AI just made protein design smarter and faster
Meet the AI tool that creates proteins that fold better, bind tighter and perform more reliably. Find out why it matters for next-generation medicines.
List view / Grid view
Meet the AI tool that creates proteins that fold better, bind tighter and perform more reliably. Find out why it matters for next-generation medicines.
Nearly a billion people are affected by chronic organ scarring, yet treatments remain limited. Now, Duke-NUS researchers have compiled a scientific ‘handbook’ of immune cell insights that could fast-track breakthroughs in fibrosis therapy.
A new study suggests statins, cheap and widely used cholesterol drugs, could be repurposed to reduce the risk of death from sepsis. Researchers reported a 39 percent drop in 28-day mortality, highlighting their potential role in critical care.
Radiopharmaceuticals represent a rapidly advancing field in oncology, using radioactive compounds to both detect and treat cancer at the molecular level. This article explores how targeted radiation is improving patient outcomes while reducing systemic toxicity.
A new study reveals that BCG, a decades-old bladder cancer treatment, reprograms the immune system at the bone marrow level, offering a new perspective into how this immunotherapy boosts the body’s defence against cancer.
5 June 2025 | By WuXi Biologics
Stop costly biologic failures. This masterclass reveals high-throughput strategies to optimize antibody leads upfront.
Despite the promise of gene therapies, automated red blood cell exchange (aRBCX) remains an underutilised therapy in the management of sickle cell disease (SCD). In this article, Dr Aaron Haubner and Carly Newton of Terumo Blood and Cell Technologies, highlight the urgent need for partnerships and equitable access to this…
Researchers at Texas A&M University have developed advanced vessel-chip technology that closely mimics the complex architecture of human blood vessels, offering a new potential platform for studying vascular diseases and accelerating drug discovery.
Researchers at the University of Michigan have engineered a herpes virus protein to enhance T cell survival and function, offering a new strategy to strengthen cancer immunotherapy.
Preclinical and clinical development are critical to the success of ADCs, where early strategic decisions regarding manufacturability and scalability can make or break a project. Iwan Bertholjotti of Lonza emphasises the importance of proactive planning to avoid costly delays and ensure smooth progress towards clinical success.
A new study from the University of Barcelona’s Institute of Neurosciences has discovered a crucial role for the RTP801 protein in astrocytes, potentially making way for future therapies aimed at slowing or reversing cognitive decline.
A new study from Central South University reveals how adenosine phosphate signalling shapes the tumour microenvironment in melanoma, offering a new biomarker for guiding personalised cancer treatment.
The world’s first translational research center dedicated to urea cycle disorders (UCDs) has been launched in Zürich, marking a significant moment in rare disease innovation.
A team of researchers have developed the first vascularised organoid model of human pancreatic islets, which could lead to further development of advanced cell therapies for diabetes.
Researchers at Mass General Brigham have developed a new gene therapy delivery system, AAV.CPP.16, that targets the lungs via nasal spray, which could offer a potential breakthrough in respiratory gene therapy.